Not all patients with CLL demand therapy. Even with all current advances, the iwCLL still recommends watchful observation for patients with asymptomatic disease.86 This suggestion is based on no less than two randomized trials comparing observation to possibly chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).Nah berbica